trending Market Intelligence /marketintelligence/en/news-insights/trending/CQL9_RPZ_1to0zC9IRA9DQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Zosano Pharma files for US FDA approval of migraine therapy

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Zosano Pharma files for US FDA approval of migraine therapy

Zosano Pharma Corp. filed an application with the U.S. Food and Drug Administration seeking approval of its non-oral migraine therapy Qtrypta.

The Fremont, Calif.-based biopharmaceutical company said Qtrypta is a formulation of the migraine drug zolmitriptan which is delivered through the company's proprietary Adhesive Dermally-Applied Microarray technology that consists of microneedles coated with the medicine.

A migraine is a powerful headache that among other things may happen with nausea, vomiting and sensitivity to light.

Zosano said in a Dec. 23 press release that the new drug application was backed by data from a phase 2/3 trial, dubbed Zotrip, which showed that the therapy helped patients achieve pain relief.

The company expects to hear from the FDA in March 2020 on whether the submission was accepted for review.